FRIDAY, April 15 (HealthDay News) -- The utilization of penile implants is low in men who have had prostate cancer treatments, including radical prostatectomy (RP) or radiotherapy (RT), but is more likely in those who have had RP than RT, according to a study published online March 22 in The Journal of Sexual Medicine.
Raanan Tal, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues examined the use of penile implants after RP or RT for prostate cancer from participants in the Surveillance Epidemiology and End Results cancer registry. Demographic and clinical predictors of implant utilization were identified for 68,558 men aged 66 years or older diagnosed with prostate cancer who were treated with RP (15,811) or RT (52,747).
The investigators found that the overall rate of implant utilization was 0.8 percent: 0.3 percent in the RT group and 2.3 percent in the RP group. Penile implant utilization was predicted by factors including the surgical treatment modality, younger age, Hispanic or black race, being unmarried, and living in the South or West.
"Penile implant utilization after prostate cancer treatment is low in the studied population. Demographic- and treatment-related factors are associated with disparities in the use of implant procedures. Younger age, black/Hispanic race, and surgical treatment for prostate cancer are predictors of higher penile [implant] utilization," the authors write.